CTOs on the Move

Vir Biotechnology

www.vir.bio

 
Vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world`s most challenging infectious diseases for which solutions are non-existent or inadequate. Vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. The company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.vir.bio
  • 499 Illinois Suite 500
    San Francisco, CA USA 94158
  • Phone: 415.906.4324

Executives

Name Title Contact Details
Marge Correa
Senior Director, Total Rewards Profile
Michael Kamarck
Chief Technology Officer Profile
Alex Bangs
Chief Information Officer Profile

Funding

Vir Biotechnology raised $66M on 08/07/2018
Vir Biotechnology raised $250M on 04/07/2020

Similar Companies

TEK Solutions Inc

TEK Solutions Inc is a Chantilly, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Forticell Bioscience

Forticell Bioscience is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Array Biopharma

Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. We have locations in CO (Boulder and Longmont), MA (Boston), and NC (Morrisville).

BlueWillow Biologics

NanoBio® is a division of BlueWillow Biologics, Inc., a privately-held biopharmaceutical company focused on developing intranasal vaccines and topical anti-infective therapies based on its patented nanotechnology platform.

Zentalis

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New York and San Diego.